Summary
The U.S. Food and Drug Administration’s staff reviewers on Tuesday raised safety concerns that GSK’s blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in patients.
Source: Reuters on MSN.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
